Background. Previous reviews of interventions to prevent sexually transmitted infections (STIs) focused mostly on human immunodeficiency virus (HIV) infection. We reviewed trials of interventions to prevent sexual transmission of any STI, employing a multilevel perspective.
heterosexual men) [1] [2] [3] [4] [5] [6] [7] [8] [9] ; types of interventions (e.g., sociobehavioral or structural) [10] [11] [12] ; or geographic regions (e.g., the United States or sub-Saharan Africa) [13] . Few have had a more general scope [14] , and most have focused on prevention of HIV infection. Many have included intervention trials with quasi-experimental study designs, convenience samples, nonbiomedical end points, and/or passive ascertainment of biomedical outcomes, all of which can lead to bias [15] . Although randomized controlled trials (RCTs) also can be biased [16] [17] [18] [19] [20] , they represent the highest level of evidence.
Clearly, a review limited to RCTs could miss important interventions. For example, a similar review of interventions to prevent perinatal STI transmission would exclude Credé's [21] demonstration that applying 1 drop of silver nitrate solution to an infant's eyes immediately after birth prevented gonococcal ophthalmia neonatorum. Credé performed a multiple time- Surgical alterations to human anatomy (e.g., male circumcision or tubal ligation) Outcome measured Acquisition STI acquisition by individuals exposed or not exposed to an intervention Transmission STI transmission to susceptible individuals by infected individuals exposed or not exposed to an intervention that targets infected individuals within a sexual dyad or within a community Complications Development of sequelae of an STI by infected or potentially infected individuals exposed or not exposed to an intervention series study, with no control or comparison group. Our approach also excludes ecological analyses of "success stories," such as the decrease in HIV infection in Thailand and Uganda after multicomponent interventions. Although important, such analyses are less amenable to cause-and-effect interpretations or to explicit definition of exactly what worked.
METHODS
This review relies, in part, on the US Preventive Services Task Force (USPSTF) criteria and methods for evidence-based development of clinical practice guidelines [22] , as well as recent suggestions for evaluation of community-based preventive interventions [23] . Early USPSTF criteria focused on the hierarchy of research design, in which evidence from at least 1 properly conducted RCT represented the reference standard [22] . The recent USPSTF Methods Work Group has added ratings of internal validity; explicit assessment of evidence at 3 different strata (the individual study, the body of evidence concerning a causal pathway linkage, and the body of evidence concerning the entire preventive service); an assessment of the quality of evidence; and assessment of benefits, harms, and costs of an intervention. Analytical framework. Anderson and May's equation , where R 0 is the rate of spread in a population, b R p bCD 0 is the transmission probability, C is the average contact rate, and D is the average duration of infectiousness-has guided the conceptualization of STI epidemiology for many years [24] but was considered to be too restrictive for this review of RCTs of prevention. To organize our analysis of trials of preventive STI interventions, we sought an inclusive framework organized according to the level of randomization and intervention (individual, group, or community); the implicit or explicit primary outcomes measured (decreased acquisition, transmission, or complications of STI); and the intervention modality used (behavior change, vaccination, use of topical microbicides, or treatment [prophylactic, curative, or suppressive therapy]) (table 1) .
Given the heterogeneity of preventive STI interventions, the many trials available for evaluation, and our intent to focus on level I evidence, we limited our analyses to randomized prevention trials with systematic, prospectively measured, objective STI outcomes. Good examples analyzing intermediate causal pathway linkages, as defined by the USPSTF (e.g., self-reported behavior changes or vaccine-induced antibody titers), are highlighted but not exhaustively reviewed. Figure 1 presents the framework, showing points of intervention to prevent STI acquisition by an uninfected individual and those to prevent STI transmission from and/or complications in infected individuals.
Clearly, a given behavioral, biomedical, or structural intervention may influence multiple outcomes. For example, a successful vaccine for human papillomavirus (HPV) or HIV infection might reduce the risk of acquisition, subsequent transmission, or complications. However, with few exceptions [25] , published trials of STI interventions, using randomization of individuals or groups, have examined only 1 of these outcomes. Thus, figure  1 represents the linkages in interventions involving an individual, a sexual dyad, or individual participants in group-level inter- ventions. In contrast, community-level trials can present morecomplex pathway linkages. For example, in community-level randomized trials of early treatment of STIs [26] [27] [28] , a decrease in prevalence or incidence of an STI (other than HIV infection) in the general population presumably reflects both decreased duration of infection and the resulting decrease in STI transmission, whereas a resulting decrease in the incidence of HIV infection at the population level could reflect the potential effect of reduced morbidity due to STI on HIV transmission or acquisition or both. Thus, in community-level trials, the putative causal pathway linkages can simultaneously influence both acquisition and transmission at a population level, necessitating a separate analytical framework (figure 2).
Search methods and inclusion criteria. Criteria for inclusion in this assessment, which were established before the literature searches were conducted, included experimental study design (RCT); biological markers of a prospectively measured, objective STI outcome; and publication in the English-language, peer-reviewed literature or presentation at international conferences during [2002] [2003] but not yet published [25, [29] [30] [31] [32] . We searched MEDLINE (http://www.ncbi.nlm.nih.gov/ entrez/query.fcgi) through 2003, using the terms "randomized/ randomised trial + STD," "controlled trial + STD," "randomized trial + STI," "controlled trial + STI," "randomized trial + vaccine," and "controlled trial + vaccine" (to identify trials involving vaccines against STIs). We also searched the Cochrane Central Controlled Trials Registry (http://www.update-software .com/clibng/cliblogon.htm) through 2003, using the terms "prevention" and "STD," "STI," "HIV," "syphilis," "gonorrhea," "C. trachomatis," "trichomonas," "chancroid," "genital herpes," or "genital HPV." We also checked reference lists of included publications and added 2 randomized trials of STI prevention known to the authors but not identified through the literature search [33, 34] .
The heterogeneity of studies reviewed precluded quantitative summary statistics; rather, we present a qualitative summary of the trials. We reviewed studies for appropriate analyses [22] and internal and external validity, judging internal validity on assembly and maintenance of comparable groups; equal, reliable, and valid measurements; clear definition of interventions; and consideration of all important outcomes. We also summarized factors influencing external validity (generalizability). Participation and rates of follow-up were taken directly from the text, when given, or were calculated on the basis of data provided in the article, when not explicitly stated. With multiple follow-up time points, we calculated and/or present the rate of follow-up on the basis of the last assessment visit. Finally, we enumerated the benefits and harms of the intervention (costs were rarely presented) (table 2) . We also separately cite and briefly discuss quasi-experimental studies; RCTs that did not meet all of the above criteria (e.g., self-reported outcome measures or passive follow-up); and examples of studies that provided objective intermediate outcomes of interest (e.g., condom use, increased screening, and correct prescription of STI therapy). Finally, we focused only on interventions designed primarily to prevent sexual transmission, acquisition, or complications of STI in adults. With one notable exception, we excluded the many important studies undertaken to prevent pregnancy, puerperal or neonatal morbidity due to STIs, or perinatal transmission. DiCenso et al. [71] have separately reviewed related interventions for the reduction of unintended pregnancies.
RESULTS
Forty-one randomized trials fulfilled our inclusion criteria for formal review (table 2) . Of these, 28 involved interventions targeting individuals, 9 targeted groups, and 4 targeted communities. Twenty-two (54%) of these 41 trials successfully reduced acquisition, transmission, or complications of STI (table 3) .
Individual-Level Interventions: Prevention of Acquisition
Of the 23 individual-level interventions to reduce STI acquisition, 4 involved behavior change; 2 used antimicrobial prophylaxis; 7 assessed STI vaccines or passive immunization; and 10 used microbicides.
Behavior change. Risk-reduction counseling was the most frequently used approach for behavior change. In Project RESPECT [36] , client-centered counseling based on the Centers for Disease Control and Prevention model for HIV counseling was as effective as a 4-session interactive-counseling intervention based on the theory of reasoned action and social cognitive theory, in reducing incident STI over a 12-month period, when compared with the efficacy of didactic messages. Assessment of the causal pathway linkages demonstrated high correlation between the intervention targets (attitudes, self-efficacy, and social norms), intentions, and behavior [72] , as well as infection status of partners [73] . The Voluntary HIV-1 Counseling and Testing (VCT) Efficacy Study also found a modest reduction in incident STI among those receiving Project RESPECT-based counseling, compared with control subjects who had received only health information. The reduction in incident STI was similar in magnitude to that observed in Project RESPECT and was associated with reported behavior change, but the reduction in STI was not statistically significant [38] . A separate intervention through individual counseling but without HIV testing, based on the AIDS Risk Reduction Model, failed to show any reduction in STI acquisition but had low rates of participation and follow-up [35] . The EXPLORE study compared 10 modules of individual counseling plus trimonthly maintenance sessions with twice-yearly Project RESPECT-based risk-reduction counseling and demonstrated a modest, nonsignificant reduction in HIV acquisition [39] . However, the causal pathway linkage of unprotected anal intercourse was significantly reduced.
Oral antimicrobial prophylaxis. Harrison et al. [40] randomly administered prophylactic minocycline or placebo to sailors returning from shore leave and found significantly reduced acquisition of gonorrhea among men who had received minocycline. However, the concomitant risk of selection of the more drug-resistant strains of Neisseria gonorrhoeae in those who acquired infection, despite prophylaxis, outweighed the benefit of reducing acquisition, and the intervention was not recommended. Kaul et al. [25] provided monthly azithromycin treatment to female sex workers (FSWs) and reported a sig-nificant reduction in incident gonococcal, chlamydial, and trichomonal infections but no effect on incidence of HIV infection. This intervention also may have reduced the duration of STI among FSWs (because of the long half-life in vivo of azithromycin), thus also reducing transmission to clients. Although results of RCTs examining antiretroviral prophylaxis against sexual acquisition of HIV in high-risk populations have not yet been published, ongoing trials are currently examining use of oral tenofovir prophylaxis for prevention of HIV acquisition in Cambodia, Cameroon, Ghana, Nigeria, Malawi, San Francisco, and Atlanta.
STI vaccines or passive immunization. The inactivated hepatitis B virus (HBV) vaccine, which was tested among MSM in the late 1970s, was the earliest successful trial of immunization of individuals against an STI [41] . During 18 months of followup, vaccine efficacy was 92%. Subsequent trials reported similarly high levels of vaccine efficacy, with use of lower vaccine doses [43, 44] , and a reevaluation of the data from the original trial reported vaccine efficacy close to 100% among those who had received all 3 doses [42] . However, the initially high cost of the HBV vaccine, the emergence of AIDS among MSM (the group donating serum from which the initial vaccine was derived), and the weak promotion of vaccines for prevention of sexual transmission all contributed to the very slow uptake of vaccination against HBV infection in groups at high risk.
In a single-blind RCT, the steady heterosexual partners of hepatitis C virus-positive patients received intramuscular injections of serum immunoglobulin every 2 months and acquired hepatitis C significantly less often than did placebo recipients (relative risk [RR], 0.09; 95% confidence interval [CI], 0.01-0.83) [45] . Outcomes were few, however, because the trial ended early when Italy mandated immunoglobulin testing (immunoglobulin had been prepared from unscreened donors).
More recently, a yeast-derived HPV type 16 vaccine was 100% efficacious in preventing persistent HPV-16 infection in young college women [48] . Phase 3 trials of a quadrivalent HPV-16, -18, -6, and -11 vaccine are under way. Two large trials of a recombinant herpes simplex virus (HSV) type 2 vaccine derived from glycoproteins D 2 and B 2 showed only very transient protection against HSV-2 acquisition [46] . However, in 2 subsequent trials of a different HSV-2 glycoprotein D-adjuvant vaccine, among persons with no serologic evidence of prior HSV-1 infection, the vaccine partially protected women (but not men) from experiencing genital herpes disease, with 73% efficacy for women in 1 trial (95% CI, 19%-91%) and 74% in another (95% CI, 9%-93%). This vaccine did not protect men or women already seropositive for HSV-1 infection [47] .
Topical microbicides used intravaginally. Early randomized trials examining intravaginal use of nonoxynol-9 (N-9) for prevention of gonococcal or chlamydial infection reported encouraging results [49] [50] [51] [52] [53] , although these trials did not adhere to all of the Consolidated Standards of Reporting Trials guidelines for rigorous RCTs. Subsequently, Kreiss et al. [54] evaluated use of the N-9-impregnated cervical sponge among FSWs in Nairobi, in a randomized placebo-controlled trial, and found significantly decreased risk of gonorrhea, significantly increased risk of genital ulcer disease and vulvitis, and a trend toward increased acquisition of HIV-1. In a later randomized, doubleblind, placebo-controlled trial of use of intravaginal N-9 film among FSWs in Cameroon, Roddy et al. [55] reported no effect on risk of HIV, gonococcal, or chlamydial infection but found an elevated risk of genital lesions. Finally, Roddy et al. [57] (in a nonblind trial, using 4.0% N-9 gel) and Richardson et al. [56] (in a double-blind trial, using 3.5% N-9 gel) reported elevated risk of acquiring gonorrhea among high-risk women in Cameroon and FSWs in Kenya, respectively, who were using N-9. Van Damme et al. [58] reported that use of 3.5% N-9 gel had no significant effect on either gonococcal or chlamydial infection but found an increased risk of HIV-1 seroconversion among FSWs from 4 countries, in a triple-blind, placebo-controlled trial. Several commentaries [74, 75] and 2 meta-analyses [76, 77] have attempted to reconcile these data. The most rigorous meta-analysis, which was restricted to RCTs, concluded that these N-9 products produced no significant reduction in risk of STI or HIV infection but showed some evidence of harm through the induction of genital lesions [77] .
Male circumcision. The cross-sectional evidence suggesting that male circumcision decreases the risk of acquiring HIV infection and chancroid is strong [78] [79] [80] [81] . Three trials currently in process in Kenya, Uganda, and South Africa have no outcome data yet available.
Individual-Level Interventions: Prevention of Transmission
Fewer (only 4) individual-level interventions have been designed and tested for prevention of transmission, and all involved curative or suppressive therapy. Studies are planned for the examination of preventing HIV transmission within HIVserodiscordant couples, through suppressive antiretroviral therapy of the seropositive partner. Meanwhile, trials involving oral antimicrobial or antiviral prophylaxis for other STIs provide interesting perspectives on this approach.
In a randomized trial during the early 1980s, Lyng and Christensen [33] showed that giving tinidazole to male partners of women treated for vaginal trichomoniasis significantly reduced recurrences, providing the evidence for current recommendations to treat male partners of women undergoing treatment for trichomoniasis. In contrast, RCTs that treated male partners of women with bacterial vaginosis (BV) have failed to reduce recurrences of BV (reviewed elsewhere [82] ). More recently, Corey et al. [34] showed that administering valacyclovir to HSV-2-positive members of serodiscordant couples reduced the incidence of symptomatic genital herpes among the uninfected part-ners. Schillinger et al. [59] evaluated patient-delivered therapy to partners of women with chlamydial infection, demonstrating a nonsignificant trend toward reduced risk of reinfection with Chlamydia trachomatis. In a more recent trial, Golden et al. [29] found a significant reduction in gonococcal or chlamydial infection, after 10-18 weeks, among patients undergoing treatment and randomly assigned to a group in which partners received expedited therapy (usually patient delivered), compared with patients whose partners received routine notification.
Individual-Level Interventions: Prevention of Complications
One intervention examined prevention of complications from STI, using a randomized trial design. Scholes et al. [60] randomly assigned women receiving care at the Group Health Cooperative of Puget Sound (Seattle, WA) to risk-based screening for C. trachomatis infection or to usual care and observed a 56% reduction in the subsequent risk of incident pelvic inflammatory disease (PID). Although this primary outcome was identified through review of the Group Health Cooperative records, we included this trial because PID is mostly a clinical diagnosis and, thus, is regularly recorded (as opposed to asymptomatic STI, which can be easily missed in studies that rely on review of records) and because those enrolled received all medical care at Group Health Cooperative facilities, which assured adequate ascertainment of case patients.
The extensive body of evidence assessing prophylaxis against opportunistic infections in HIV-infected individuals is beyond the scope of this assessment and has been reviewed elsewhere [83, 84] , as has the efficacy of combination antiretroviral therapy in the prevention of progression to AIDS [85] . Similarly, several trials have shown that antiviral suppression decreases clinical and virologic recurrences of genital herpes and have been reviewed elsewhere [86] . An unusual recent study randomly assigned women with cervical intraepithelial neoplasia (CIN) and their male partners to groups that either used or did not use condoms and demonstrated more-frequent regression of CIN (53% vs. 35%, respectively;
) and clear-P p .03 ance of HPV (23% vs. 4%, respectively; ) in the group P p .02 that used condoms [87] .
Group-Level Interventions: Prevention of Acquisition
Five trials used methods targeting behavior change, in smallgroup settings, to reduce acquisition of STIs, and 4 trials used large-group settings to test interventions targeting behavior change, oral antimicrobial prophylaxis, or introduction of the female condom.
Behavior change. One trial compared multisession smallgroup counseling to standard 2-session counseling for prevention of HIV infection and found no difference in risk behaviors or in new cases of STI [61] . The National Institute of Mental Health (NIMH) Multisite Prevention Trial evaluated smallgroup risk-reduction discussions and observed decreases in both STI symptoms and incident gonococcal infection among men, as measured by interim chart review, but found no significant difference in gonorrhea detected by ligase chain reaction in urine, after 12 months [62] . With a 3-session smallgroup intervention for minority women that was guided by the AIDS Risk Reduction Model, Shain et al. [63] reported a 49% reduction in incident gonococcal and chlamydial infection at 12 months; a subsequent analysis of the causal pathway linkages demonstrated nicely how the reduction in STI was mostly attributable to 4 of the behavioral factors targeted by the intervention [64] . A 16-session intervention that provided women with training in safe-sex skills and behavioral, cognitive, and communication skills, as well as in skills to support the longterm maintenance of behavior changes, also reduced new cases of STI 12 months after the intervention [66] . However, a 6-session small-group intervention using interactive video, role play, guided fantasy, discussion emphasizing communal mastery (effects of individual behavior on community), and negotiation skills found that women who participated in the intervention were no less likely to have an STI at follow-up than were women who received standard care [65] . In contrast, Boyer et al. [30] found that women in military recruit-training platoons randomly assigned to an information, motivation, and behavioral skills intervention were significantly less likely than women in control platoons to experience an STI or unplanned pregnancy after the intervention.
Oral antimicrobial prophylaxis. In Benin and Ghana, community clusters of FSWs randomly assigned to receive monthly alternation of azithromycin and ciprofloxacin experienced no reduction in chlamydial infection and only a trend toward reduced gonococcal infection [31] . Potential selection of antibiotic-resistant microorganisms was not examined. This predominantly group-level intervention (a number of participants in Benin were randomly assigned individually) is analogous to the individual-level trial by Kaul et al. [25] , mentioned earlier, that targeted both acquisition and transmission.
Provision of female condoms. Kenyan plantations randomly assigned to intensive information, education, and communication (IEC) plus distribution of female and male condoms or IEC plus distribution of male condoms only demonstrated no difference in incidence of STI between groups [67] . Thai brothels randomly assigned to receive male or female condoms experienced a nonsignificant 16% decrease in incident STI, compared with brothels that received male condoms only [68] .
Community-Level Interventions
The 4 community-level randomized trials identified all had multiple targets and outcomes. All essentially sought to reduce both HIV transmission by infected persons and HIV acquisition by susceptible persons, through reduction of the incidence of STI. With regard to STIs other than HIV infection, however, all sought to reduce the prevalence and transmission of STIs by shortening the duration of STI infectiousness within the general population.
Mixed modalities. Kamali et al. [28] used a mixed-modality approach to target both transmission and acquisition in a community-level randomized trial in Masaka, Uganda. One set of communities received IEC alone, one set received IEC plus implementation of syndromic management of STIs, and the control set received only community-development assistance. Oddly, only the IEC-intervention arm experienced decreased incidence of HSV-2 seroconversion, whereas participants receiving the combined intervention experienced decreased incidence of syphilis and gonorrhea. Condom use increased in all groups, but incidence of HIV-1 infection did not differ between groups. In the Mema Kwa Vijana study in Mwanza, Tanzania, Hayes et al. [32] randomly assigned 20 communities to a 4-component intervention consisting of inschool sexual and reproductive health education, enhanced reproductive health services for youth, condom distribution, and community activities. Preliminary analyses showed no differences between intervention and control communities in seroincidence of HIV or HSV-2, incidence of other STIs, or pregnancy outcomes, despite improvements in knowledge and reported behaviors.
Syndromic or mass treatment. Grosskurth et al. [27, 88] implemented improved syndromic treatment of STIs, in Mwanza, Tanzania, and demonstrated a 38% reduction in incidence of HIV infection. They also observed reductions in incidence of symptomatic urethritis among men and in prevalence of syphilis seroreactivity (rapid plasma reagin titer of у1:8), but they did not see an effect on gonococcal or chlamydial infection among antenatal women [70] . In the Rakai, Uganda, trial of repeated mass treatment of STIs, the reduction in prevalence of Trichomonas vaginalis infection among women was significantly greater in communities randomly assigned to receive mass treatment; however, when intervention communities were compared with control communities, there was no significant reduction in the prevalences of gonorrhea, chlamydial infection, new syphilis seroreactivity, and BV or in the interim history of urethral or vaginal discharge or of genital ulcer disease and no effect on the incidence of HIV infection, at 10 months after each round of treatment [26] . However, in a subanalysis of participants who were pregnant when given mass treatment, Gray et al. [69] demonstrated reduction in the prevalence of several STIs among women tested near delivery (∼4 months after receiving the mass treatment) and also observed significant reductions in potential STI-related pregnancy, puerperal, and neonatal morbidity. Here, the reduced prevalences of STIs at delivery acted as causal pathway linkages between the masstreatment intervention and the reduced pregnancy, puerperal, and neonatal morbidity.
Trials with Passive Follow-up, Nonrandomized Design, or Intermediate Outcomes
Twenty-one additional studies involved quasi-experimental design, passive follow-up, or only intermediate outcomes, as briefly cited below. Another 26 studies that are not discussed further had no biological measure of STI outcomes (23 studies), no comparison group (1 study), no specific intervention (1 study), or had acknowledged concerns with internal validity (1 study).
Individual-level randomized trials with passive follow-up. The NIMH trial discussed above illustrates how results may differ for passive ascertainment of the incidence of STI through review of records versus ascertainment of incidence of STI through active testing [62] . Similarly, 3 individual-level randomized trials using methods targeting behavior change that used chart reviews [89] , reported symptoms [90] , or self-reported STI [91] all found no decreased incidence of STI.
Group-level randomized trials with passive follow-up. Six small-group trials also relied on passive ascertainment of STI outcomes. One reported decreased incidence of STI (identified through state surveillance reports) among minority men participating in a video and discussion group [92] . Two small-group interventions (instruction on condom use [93] and discussion and role playing for condom negotiation [94] ) demonstrated efficacy for men but not for women; another trial with randomization of women to hierarchical counseling (multiple types of preventive barrier methods) versus a single-method message reported no difference in disease recurrence rates, as identified by review of electronic clinic records [95] . Notably, a 1-day, small-group, cognitive/ behavioral intervention for MSM led to a nonsignificant decrease in unprotected anal intercourse, but a significant increase in incidence of STI was detected in the intervention group (illustrating the importance of including objective measures of incidence of STI in such studies); rates of follow-up were low [96] .
Individual-level nonrandomized trials. In a before-after comparison, FSWs in Côte d'Ivoire who received intensive monthly STI screening experienced a significant reduction in seroincidence of HIV-1 (RR, 0.42; 95% CI, 0.18-0.96), relative to the seroincidence rate before the invervention began, that was likely mediated through increased consistent condom use and decreased incidence of gonorrhea and trichomoniasis in both groups [97] . Another individual-level study (with randomization of participants within STI clinics but not within family-planning clinics) showed no reduction in incidence of C. trachomatis infection, despite increased condom use, among adolescent girls attending STI and family-planning clinics using a Health Belief Model-based intervention [98] .
Group-level nonrandomized trials. In a nonrandomized group-level trial, units of Thai military recruits received a mul-ticomponent behavioral intervention, and a 180% reduction in STI recurrence was reported, compared with that in control units [99] . Although the units were considered to be comparable, recruits were not randomly assigned to the intervention and control units, and the trial relied on passive identification of STI through clinical diagnosis or reports of symptoms. Another trial tested a group discussion on condoms presented in clinic waiting rooms, compared with waiting room sessions in which no discussion was held, and reported a nonsignificant 50% reduction in repeat attendance at the clinic with a subsequent STI, for the intervention group [100] .
Community-level nonrandomized trials. Two structural interventions demonstrated significant decreases in STI. In serial prospective cohorts in 1991 and 1993, Celentano et al. [101] enrolled Thai military conscripts in longitudinal studies of STI and HIV infection. Following the Thai government's implementation of the 100%-condom program for brothel-based commercial sex work, these investigators documented a 10-fold decrease in incidence of STI and a 5-fold decrease in incidence of HIV infection, after 2-year follow-up intervals. The Seattle Social Development Project enrolled consenting fifth-grade students in public schools serving high-crime areas into a longitudinal panel study of a multicomponent intervention composed of teacher training in classroom instruction and management, child social and emotional skill development, and parent training [102] . The African American subset of the full intervention group experienced a decrease in self-reported STIs by age 21 years (odds ratio [OR], 0.11;
). P ! .01 Randomized trials with intermediate outcomes. The following 6 illustrative randomized trials targeted and objectively measured intermediate outcomes. US clinics randomly assigned to a clinical practice-improvement program reported significantly higher rates of screening for chlamydial infection than did control clinics (65% vs. 21%, respectively; ) [103] P ! .001 and a trend toward lower rates of chlamydial infection (5.8% vs. 7.6%, respectively). In Denmark, young men and women in a population-based sample were randomly assigned to receive a home sampling kit directly in the mail, a reply card to request a home sampling kit, or usual care; persons who were sent the home kit were screened significantly more often for chlamydia (OR, 19.1; 95% CI, 16.0-22.8) [104] . In a French mixed-modality community intervention consisting of free screening and treatment for minors, condom distribution, public IEC, and IEC for health professionals, women (but not men) in the experimental departments reported multiple partners less often and were tested significantly more often for C. trachomatis infection [105] .
In Lima, Peru, 14 districts were paired and randomly assigned to receive workshops for pharmacy workers in the management of STI syndromes or a 1-day seminar for pharmacy workers on the treatment of diarrhea. Male and female simulated patients observed that pharmacies in intervention districts offered significantly better management of STI syndromes than did pharmacies in control districts [106] . In another cluster-randomized trial, Harrison et al. [107] tested a health worker-training intervention, using STI syndrome-treatment packets, for the quality of management of STI cases in primary-care clinics in KwaZulu/Natal and reported significant increases in the proportion of simulated patients who were treated correctly.
Peterman et al. [108] randomly assigned people with syphilis to participate in partner notification by patients within 2 days; immediate partner notification by disease-intervention specialists; or immediate partner notification by disease-intervention specialists, with an optional blood draw in the field. In this analysis of cost-effectiveness, all 3 approaches had similar success in locating and treating partners.
Finally, in Managua, Nicaragua, where a health ordinance required motels to provide condoms to clients when requested, motels patronized for commercial or noncommercial sex were randomly assigned to providing condoms to clients when requested at check-in, always offering condoms at check-in, or placing condoms on each bed before check-in. After guests checked out, study personnel counted used condoms left behind. Offering condoms at check-in or placing condoms on the bed both resulted in significant increases in condom use [109] . Tables 2 and 3 summarize the strongest available experimental evidence on the effectiveness of preventive STI interventions. Several previous reviews have considered only trials of behavioral interventions [2, [4] [5] [6] 10 ], whereas we assessed trials of vaccines, microbicides, and treatment, along with trials of interventions targeting behavior change. Each of these modalities depends on behavior change, and even interventions that primarily targeted behavior change often included biomedical components (e.g., partner notification and treatment) or use of a pharmaceutical product (i.e., condoms). These intervention modalities represent a continuum, rather than distinct and separate "behavioral" and "biomedical" activities, and, when considered together, provide a complete picture of the full spectrum of current approaches to STI prevention. Most trials involved individual-level interventions to reduce STI acquisition. There was a notable dearth of RCTs with objective outcome measures for STI and HIV infection prevention among MSM, since the original HBV vaccine trials 130 years ago. Behavior change was the most commonly used modality, followed by treatment. No randomized trials examined structural interventions, and few evaluated STI screening. Overall, topical N-9 microbicide trials, although numerous, resulted in no net benefit, and several resulted in harm. In contrast, HBV, HPV, and the 2 most recently reported HSV vaccines were beneficial; only the HBV vaccine is available commercially but still is little used globally to prevent sexual acquisition of HBV infection. Although vaccines, screening, and many therapies showed preventive benefit, they are organism specific and often prevent only 1 type of outcome after a risky exposure.
DISCUSSION
Results of 32 of the 41 RCTs identified have been reported since 1990. Five years ago, a discussion of the effectiveness of behavioral interventions cited only 2 examples of trials using biological end points [110] . We identified at least 11 individuallevel, group-level, or community-level randomized trials of behavioral interventions, several of which reduced STI acquisition. Components of interventions targeting behavior change include the underlying behavioral theory, context, target population, duration of the intervention, modality, and quality of delivery. Success or failure may depend on any of these components. Among the behavioral interventions reviewed, those that showed no effect were theory based as often as those that demonstrated benefit, and no single underlying behavioral theory or approach (e.g., skills building, counseling, and motivational interviewing) was more often successful than another. Interventions delivered in small-group settings were as effective as those delivered to individuals. No obvious characteristics of study populations or recruitment sites differentiated successful from unsuccessful interventions targeting behavior change, although the VCT Efficacy Study showed a greater reduction in unprotected sex only with nonprimary partners [38] , and causal pathway analyses in 2 studies of effective interventions highlighted components that contributed to their success [37, 64] . All trials of successful counseling interventions involved at least 2 counseling sessions [36, 62, 63, 66] . However, 2 interventions of 4 and 6 sessions had no effect on the incidence of STI [35, 90] . Of the 5 STI clinic-based behavioral interventions reviewed [35, 36, 61, 63, 66] , 3 showed at least some efficacy [36, 63, 66 ], 1 did not [35] , and 1 showed no difference between 2 behavioral interventions, both of which had been previously found to be more efficacious than didactic messages [61] . In general, effect sizes were often small and not sustained beyond 6-12 months. As a result, problems of small sample size [35] and lack of power [38] may have contributed to the absence of a significant reduction in incidence of STIs in some studies. Results of the effect of the EXPLORE study on STIs other than HIV infection have not yet been published and will be of interest. Finally, results of 2 RESPECT-based intervention trials raised serious questions about the sustainability of an effect on STI and HIV infection [38, 39] . Whether any of the effective interventions have been widely implemented in any setting is not clear.
Subanalysis of the NIMH Multisite Prevention Trial suggested, through modeling, that the effect of a particular behavior change on the risk of STI depended on the type of STI [111] . Number of partners was more predictive of risk for highly infectious STIs than for HIV infection (which has a much lower probability of transmission), whereas number of unprotected sex acts was more predictive of risk for HIV infection than for highly infectious STIs. If the modeling assumptions are valid, the behavioral interventions reviewed here might have different effects in populations with different baseline prevalences of STIs and on the incidence of STIs of different infectiousness.
Individual-level studies using prophylactic treatment were almost uniformly successful in reducing incidence of STI. However, the extent to which repeated pre-or postexposure prophylactic treatment engenders antimicrobial resistance in the pathogen(s) targeted or in other microbes present in the host remains a major concern [40] . Development of antimicrobial resistance will likely vary by organism and chemoprophylactic agent; future trials of chemoprophylaxis must systematically examine these potential outcomes. Current consensus recommendations for postexposure chemoprophylaxis to prevent sexual acquisition of STI pathogens are mostly context specific and rarely based on data from randomized trials, but they include antimicrobial prophylaxis for victims of sexual assault [112] and antiretroviral prophylaxis for health workers occupationally exposed to HIV infection [113] .
Other RCTs of preventive STI interventions are now under way and include examination of male circumcision; control of STIs in high-risk populations, to reduce transmission in the general population; school-based sex education; suppression of genital herpes recurrences, to prevent acquisition or transmission of HIV-1 in HIV-serodiscordant couples; and early treatment of HIV infection in HIV-serodiscordant couples, to prevent transmission to the seronegative partner. Phase 3 trials of topical microbicides other than N-9 are planned, as are phase 3 trials of HIV vaccines, and phase 3 trials of HPV and HSV vaccines are under way.
Given the complex influences of population-level prevalence, mixing patterns, individual behavior, and social norms on STI transmission, many have hypothesized that community-level interventions that simultaneously address many of these factors would be more effective than either individual-or group-level interventions. However, current evidence remains mixed. The Mema Kwa Vijana study, the most-integrated community-level intervention thus far, demonstrated no reduction in the incidence of STIs or HIV infection. As discussed by Korenromp et al. [114] in this issue of the Journal of Infectious Diseases, the equivocal results from the published community-level trials of HIV infection prevention highlight the difficulty in assessing the effects of a single intervention in preventing the complex determinants of the transmission and acquisition of HIV infection and STIs in different populations at different times. This is further complicated by threats to internal validity, such as overreporting of intervention behaviors or suboptimal outcome measures, which potentially bias results toward the null hypothesis. Community-level randomized trials of antiretroviral therapy and other components of HIV infection/AIDS care in developing countries seem to be problematic for ethical reasons, and quasi-experimental approaches with careful evaluation offer alternative opportunities for documenting the community-level effect of such interventions.
To date, most evaluations of preventive interventions have been proof-of-concept trials. Efficacy trials, whether for prevention or treatment of STI, are often costly, and many more will be needed in the near future. Given the potentially high costs of such trials, criteria for prioritizing and selecting interventions warranting evaluation are imperative. These criteria could include (1) ethical considerations; (2) feasibility, as determined by cost, acceptability, safety, likelihood of adherence, and sustainability; (3) duration of benefit; (4) scope, spectrum, and importance of infection(s) prevented; (5) probability of reducing versus increasing risk taking at individual, group, or population levels; (6) contribution of target population to transmission; and (7) strength of evidence from preclinical, phase 1, and phase 2 studies. A partial list of examples meeting many of these criteria could include trials of vaccines that potentially produce longlived immunity against important pathogens; interventions to achieve sustained reduction in transmissibility or in susceptibility to acquisition and/or complications (e.g., male circumcision); behavioral interventions undertaken among very young people, to reduce acquisition and transmission of a broad spectrum of STIs before risk-taking patterns are established; and some structural interventions. Furthermore, as we move from initial efficacy trials to testing the effectiveness of successful interventions in other settings, the incorporation of outcome and impact evaluations and cost-benefit analyses will be increasingly important, to assure that limited resources are effectively utilized.
Limitations to this review include the potential for publication bias and the restricted focus on RCTs with prospectively measured, objective STI outcomes. The results from the 4 trials presented at international conferences in [2002] [2003] but not yet published should be interpreted with caution, since they have not yet been peer reviewed. Although many of these trials lacked analyses of causal pathway linkages, we included examples examining these intermediate outcomes (e.g., markers of behavior change, condom use, screening, and improved treatment), to illustrate studies of this type. Finally, some interventions (e.g., structural interventions such as the Thai 100%-condom program) are not easily evaluated in an RCT design, and many public health interventions not tested by RCTs (such as parachute use [115] ) have enormous preventive benefits. Thus, well-conducted nonrandomized studies and even ecological analyses of nonexperimental interventions or other efforts to explain "success stories," such as the decreasing prevalences of HIV infection in Uganda, should not be discounted.
In summary, although many trials of preventive STI interventions have lacked experimental design, systematic measurement of STI outcomes, or careful attention to intermediate causal pathway linkages, this review highlights the many rigorously designed and evaluated preventive interventions undertaken at the individual, group, and community levels. Sadly, only 1 trial thus far has demonstrated significant effect on sexual transmission of HIV infection [27] , and, since the HBV vaccine trials of the late 1970s, none has yet had any definite effect on STI transmission among MSM. Furthermore, we identified no RCTs of preventive interventions with objective STI outcomes among HIV-infected persons. Remarkably few of the effective STI interventions seem to have been widely implemented-for example, perhaps only routine treatment of male partners of women with trichomoniasis; screening women for chlamydial infection; and, to a very limited extent, immunization of those still at high risk for sexual acquisition of HBV infection. Systematic evaluation of the global extent and quality of the uptake of effective preventive STI interventions is clearly warranted. Interestingly, almost every trial presents unique intervention designs that are different from those in previous trials. We found few examples of the replication and evaluation of successful interventions in other settings. Exceptions included the replication of the HBV, HSV, and HPV vaccine studies, supported by the pharmaceutical industry, and the evaluation of syndromic management of STI in Masaka, Uganda, after the similar study in Mwanza, Tanzania. Domestic and international public health agencies must give more attention to the methodologies and support required to rigorously evaluate the effectiveness of successful intervention strategies during scale-up and implementation in new settings, rather than to only the support of trials of new interventions.
